parathyroid hormone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4936 68893-82-3

Description:

MoleculeDescription

Synonyms:

  • parathyroid hormone
  • natpara
  • human parathyroid hormone
  • human recombinant parathyroid hormone
  • parathormone
  • ALX1-11
  • rhPTH
  • parathyrin
  • preotact
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
  • Molecular weight: 9424.76
  • Formula: C408H674N126O126S2
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 4123.69
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 24, 2017 EMA TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
Jan. 23, 2015 FDA NPS PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Recalled product 2535.79 32.56 362 5290 1041 63482329
Blood calcium decreased 1318.13 32.56 331 5321 26120 63457250
Hypocalcaemia 1138.94 32.56 306 5346 31407 63451963
Blood calcium abnormal 492.10 32.56 87 5565 1181 63482189
Tetany 366.79 32.56 73 5579 1928 63481442
Inappropriate schedule of product administration 348.18 32.56 174 5478 103791 63379579
Blood calcium increased 333.04 32.56 90 5562 9260 63474110
Muscle spasms 307.76 32.56 184 5468 155966 63327404
Paraesthesia 260.86 32.56 166 5486 156800 63326570
Bone pain 184.01 32.56 92 5560 54549 63428821
Product dose omission issue 122.46 32.56 126 5526 234187 63249183
Hypercalcaemia 93.19 32.56 47 5605 28275 63455095
Nephrolithiasis 86.22 32.56 51 5601 41933 63441437
Product availability issue 76.76 32.56 24 5628 4097 63479273
Hypoaesthesia 62.69 32.56 76 5576 168317 63315053
Device issue 59.84 32.56 33 5619 23748 63459622
No adverse event 59.18 32.56 40 5612 41365 63442005
Hypoparathyroidism 56.92 32.56 13 5639 665 63482705
Product supply issue 53.64 32.56 15 5637 1740 63481630
Product storage error 46.78 32.56 24 5628 14932 63468438
Product quality issue 45.02 32.56 32 5620 35833 63447537
Urine calcium increased 42.08 32.56 7 5645 64 63483306
Calciphylaxis 37.49 32.56 13 5639 3059 63480311
Hypercalciuria 37.09 32.56 8 5644 314 63483056
Feeling abnormal 36.81 32.56 55 5597 148337 63335033
Incorrect dose administered 36.23 32.56 35 5617 59933 63423437
Muscle twitching 35.47 32.56 22 5630 19646 63463724
Product distribution issue 33.87 32.56 10 5642 1406 63481964
Hypocalcaemic seizure 33.21 32.56 5 5647 22 63483348
Expired device used 33.13 32.56 8 5644 521 63482849

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Recalled product 434.92 47.68 53 510 294 34956074
Hypocalcaemia 190.24 47.68 49 514 24240 34932128
Blood calcium decreased 154.32 47.68 35 528 10049 34946319
Blood calcium abnormal 67.13 47.68 11 552 557 34955811

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Recalled product 1138.06 37.43 161 4136 793 79739298
Blood calcium decreased 1055.24 37.43 260 4037 31559 79708532
Hypocalcaemia 536.67 37.43 169 4128 49755 79690336
Inappropriate schedule of product administration 318.15 37.43 151 4146 133477 79606614
Blood calcium increased 288.55 37.43 74 4223 10326 79729765
Muscle spasms 285.43 37.43 153 4144 174577 79565514
Blood calcium abnormal 256.13 37.43 47 4250 1342 79738749
Tetany 253.63 37.43 52 4245 2676 79737415
Paraesthesia 248.14 37.43 140 4157 176183 79563908
Bone pain 173.18 37.43 76 4221 55666 79684425
Product dose omission issue 149.48 37.43 116 4181 247421 79492670
Hypoaesthesia 63.22 37.43 62 4235 179290 79560801
Product distribution issue 59.43 37.43 14 4283 1366 79738725
Device issue 59.21 37.43 29 4268 27079 79713012
Hypercalcaemia 57.79 37.43 32 4265 38398 79701693
Expired device used 57.32 37.43 11 4286 400 79739691
Nephrolithiasis 53.02 37.43 34 4263 53257 79686834
Product availability issue 44.85 37.43 14 4283 3933 79736158
Blood magnesium decreased 40.09 37.43 19 4278 16493 79723598
Product supply issue 39.75 37.43 11 4286 2037 79738054
Product quality issue 39.67 37.43 24 4273 33916 79706175

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H05AA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
CALCIUM HOMEOSTASIS
PARATHYROID HORMONES AND ANALOGUES
Parathyroid hormones and analogues
FDA CS M0015931 Parathyroid Hormone
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
FDA EPC N0000180851 Parathyroid Hormone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypoparathyroidism indication 36976004 DOID:11199




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Parathyroid hormone/parathyroid hormone-related peptide receptor GPCR AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D05364 KEGG_DRUG
4034355 VUID
N0000191550 NUI
9002-64-6 SECONDARY_CAS_RN
4034355 VANDF
CHEMBL2108078 ChEMBL_ID
DB05829 DRUGBANK_ID
1427222 RXNORM
232515 MMSL
23408 MMSL
d06650 MMSL
002141 NDDF
4076007 SNOMEDCT_US
C0030520 UMLSCUI
D010281 MESH_DESCRIPTOR_UI
8441 INN_ID
N19A0T0E5J UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0202 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 25 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0202 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 25 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0202 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 25 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0202 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 25 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0204 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 75 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0204 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 75 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0204 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 75 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0204 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 75 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0205 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0205 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0205 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 ug SUBCUTANEOUS BLA 30 sections
NATPARA (parathyroid hormone) HUMAN PRESCRIPTION DRUG LABEL 1 68875-0205 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 ug SUBCUTANEOUS BLA 30 sections